Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Bepirovirsen (Vial vs PFS SSD)
NCT06058390Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bepirovirsen in hepatitis B (HBV) (4 arms), sponsored by GSK. Primary endpoints: Maximum Observed Plasma Concentration at 1512 hours and Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity at 1512 hours. Started Oct 2023; status: completed.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06058390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058390.